About Ainos, Inc.
https://ainos.comAinos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications.
CEO
Chun-Hsien Tsai
Compensation Summary
(Year 2023)
Salary $95,912
Bonus $16,212
Stock Awards $1,172,899
Total Compensation $1,285,023
Industry Biotechnology
Sector Healthcare
Went public January 8, 2021
Method of going public Dual Listing
Full time employees 44
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-30 | Reverse | 1:5 |
| 2023-12-14 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 4
Overall Score 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $8.63 M
52w High $4.75
52w Low $1.61
P/E -0.49
Volume 25.73K
Outstanding Shares 4.82M
About Ainos, Inc.
https://ainos.comAinos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.17K ▼ | $2.79M ▼ | $-2.93M ▲ | -135.29K% ▼ | $-0.64 ▲ | $-1.55M ▲ |
| Q2-2025 | $4.66K ▼ | $3.75M ▲ | $-4.08M ▼ | -87.6K% ▼ | $-0.99 ▲ | $-2.71M ▼ |
| Q1-2025 | $106.21K ▲ | $3.25M ▼ | $-3.29M ▲ | -3.09K% ▼ | $-207.15 ▼ | $-1.93M ▲ |
| Q4-2024 | $0 | $4.63M ▲ | $-4.65M ▼ | 0% | $-0.49 ▼ | $-3.28M ▼ |
| Q3-2024 | $0 | $3.04M | $-3.7M | 0% | $-0.33 | $-2.22M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.13M ▼ | $22.68M ▼ | $12.63M ▲ | $10.04M ▼ |
| Q2-2025 | $1.22M ▼ | $23.92M ▼ | $12.48M ▼ | $11.44M ▼ |
| Q1-2025 | $2.63M ▼ | $26.35M ▼ | $13.23M ▼ | $13.12M ▼ |
| Q4-2024 | $3.89M ▼ | $28.82M ▼ | $13.3M ▼ | $15.52M ▼ |
| Q3-2024 | $5.16M | $31.37M | $13.35M | $18.02M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.93M ▲ | $-1.18M ▲ | $4.93K ▲ | $1.13M ▲ | $-94.97K ▲ | $-1.19M ▲ |
| Q2-2025 | $-4.08M ▼ | $-1.35M ▼ | $2.54K ▲ | $-295.51K ▼ | $-1.41M ▼ | $-1.34M ▼ |
| Q1-2025 | $-3.29M ▲ | $-1.22M ▼ | $-20.59K ▼ | $14.61K ▲ | $-1.26M ▼ | $-1.26M ▼ |
| Q4-2024 | $-4.65M ▼ | $-864.23K ▲ | $13.29K ▲ | $-270K ▲ | $-1.26M ▲ | $-865.14K ▲ |
| Q3-2024 | $-3.7M | $-1.48M | $-18.79K | $-1.48M | $-2.86M | $-1.49M |
CEO
Chun-Hsien Tsai
Compensation Summary
(Year 2023)
Salary $95,912
Bonus $16,212
Stock Awards $1,172,899
Total Compensation $1,285,023
Industry Biotechnology
Sector Healthcare
Went public January 8, 2021
Method of going public Dual Listing
Full time employees 44
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-30 | Reverse | 1:5 |
| 2023-12-14 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 4
Overall Score 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0